65,437 trials
Gastrointestinal Stromal Tumors · Soft Tissue Sarcomas
Primary: Change in Standardised Uptake Value (SUV)Max at Day 8, Central Review, (GIST) Gastrointestinal Stromal Tumours Patients. — -0.515 g/mL
Pneumococcal Infections
Primary: Percentage of Participants With a New Acquisition of Serotype 6A' (6A + 6C) or 19A Combined 1 Month After the Infant Series to 24 Months of Age — 20.0; 36.0 percentage…
HIV Infections
Primary: Linkage to Care of Newly Diagnosed HIV Infected Participants — 0; 7; 0; 4 participants
Influenza
Primary: Geometric Mean Antibody Titres for Haemagglutination Inhibition (HI) Antibodies Against Fluarix Vaccine Containing H1N1 Strain. — 150.1; 150.3; 646.8; NA Titres
Chronic Otitis Media
Primary: Number of Participants With Otomicroscopic Signs of Otorrhea in Either Ear — 13; 27; 15; 23 participants
AML · Acute Myeloid Leukemia · Myelodysplastic Disorders
Primary: Maximum Tolerated Dose (MTD) — 400 milligrams/twice a day (BID)
Influenza
Primary: Seroprotection Pre- and Post- Vaccination — 18.5; 12.5; 19.1; 15.4 % of Participants
HIV Infections
Primary: Percentage of Patients That Experience 10% Decline in Triglycerides From Baseline to Week 24. — 80; 73 percentage of patients
Attention Deficit Disorder With Hyperactivity
Primary: Brain Oxygenation Level Dependent Signal in the Fusiform Gyrus and the Amygdala on Concerta vs. Placebo — 1.79; 0.58; 1.43; 0.77 Face-Shape BOLD signal difference
Coronary Artery Stenosis · Coronary Arteriosclerosis · Coronary Artery Disease
Primary: Adjudicated Composite Rate of All Death, All MI and Target Vessel Revascularization (TVR). — 21.5; 22 Percentage of Participants
Neurofibromatosis 1 · Neurofibroma, Plexiform
Primary: Median Time to Disease Progression — 13.2 Months
Major Depression
Primary: Montgomery Asberg Depression Rating Scale (MADRS) — 22.629; 26.102; 29.455 Score on a scale — p=.018
Prostate Cancer
Primary: Number of Patients With a PSA Response — 4; 27 participants
Drug Induced Liver Injury
Primary: Serum Level of Acetaminophen-cysteine (APAP-Cys) Protein Adducts — 0.0; 0.3; 0.3; 0.4 nmol/mL
Multiple Sclerosis
Primary: Annualized Aggregate Relapse Rate (ARR) During Months 0 to End of Study(Core [CFTY720D2301/NCT00289978] and Extension Study) — 0.164; 0.185; 0.357 Relapses per year